These can not only identify acquired ALK resistance mutations and other actionable alterations, but also monitor the tumor remission status and emergence of high-risk features, for example acquisition of TP53 mutations (31), in a minimally-invasive manner (32, 33). This evidence concerns the gene ALK and neoplasm.